EARS Net Report, Quarter

Size: px
Start display at page:

Download "EARS Net Report, Quarter"

Transcription

1 EARS Net Report, Quarter March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased further to 1.4% [Figure 1] and the proportion of BSI caused by multi drug resistant (MDR; displaying resistance to three or more antimicrobial classes) E. coli increased further to 14. [Figure 4] Staphylococcus aureus: The proportion of S. aureus BSI that were meticillin resistant (i.e. MRSA) decreased further to 2.3% [Figure 5] Enterococcus faecium: The proportion of E. faecium BSI that were vancomycin resistant (i.e. VREfm) decreased to 43.1%. However, Ireland remains the only EU country with a VREfm proportion in excess of [Figure 7] Klebsiella pneumoniae: The proportion of patients with invasive infections caused by K. pneumoniae producing extended spectrum β lactamases (ESBLs) increased to 18.4%, which is over double what it was in 212 (8.8%) [Figure 13] The proportion of patients with invasive infections caused by K. pneumoniae belonging to a particular MDR profile, or MDRKP phenotype, which exhibits ESBL production and non susceptibility to both ciprofloxacin and gentamicin, increased to 12.3%. This reflects a dramatic increase when compared with 21, when only 2.2% of invasive K. pneumoniae infections belonged to this strain [Figure 19] Full participation by all 41 microbiology laboratories serving all acute hospitals in the Republic of Ireland resulting in 1% coverage of the population * 213 data provisional to the end of Q4 Background The European Antimicrobial Resistance Surveillance System (EARSS) was established in 1999 in response to the growing threat of antimicrobial resistance in Europe. In January 21, EARSS was taken over by the European Centre for Disease Control (ECDC) becoming the European Antimicrobial Resistance Surveillance Network (EARS Net). EARS Net comprises a network of over 9 microbiological laboratories serving over 15 hospitals in 3 countries that collects routinely generated antimicrobial susceptibility testing data on invasive infections caused by eight important bacterial pathogens: Escherichia coli Staphylococcus aureus Enterococcus faecium Enterococcus faecalis Klebsiella pneumoniae Streptococcus pneumoniae Pseudomonas aeruginosa Acinetobacter spp. Since 21, all laboratories (41 as of Jan 212) serving all acute hospitals (47 public and 12 private) in the Republic of Ireland participate in EARS Net representing 1% coverage of the population. Results Summaries of the annual (26 213) and quarterly (Q1 212 Q4 213) data submitted on all pathogens are shown in Tables 1 and 2, respectively. Table 3 shows a summary of the key resistance data by pathogen and HSE Area for 213. Data correct as of 3/3/214 Report produced by the Irish EARS Net Steering Group with special thanks to all the participating laboratories for their continued support and commitment to this surveillance system Health Services Executive (HSE) Health Protection Surveillance Centre (HPSC) Middle Gardiner Street Dublin 1, Ireland Page 1 of 18

2 Table 1. Summary of EARS Net data by pathogen and year (data correct as of 3/3/214) Pathogen ** Number laboratories by year end E. coli %Ampicillin R* %3GC R* %ESBL producers* %Ciprofloxacin R* %Gentamicin R* %Gentamicin/Amikacin/Tobramycin R* %Carbapenem 1 R* %MDR* Number laboratories by year end S. aureus Number Meticillin R (or MRSA) %Meticillin R (or MRSA) Number laboratories by year end E. faecium %Ampicillin R* %Vancomycin R (VREfm) %HLG R* %MDR* Number laboratories by year end E. faecalis %Ampicillin R* %Vancomycin R (VREfa) %HLG R* Number laboratories by year end K. pneumoniae %Ampicillin R* %3GC R* %ESBL producers* %Ciprofloxacin R* %Gentamicin R* %Gentamicin/Amikacin/Tobramycin R* %Carbapenem 1 R* %MDRKP 2 * %MDR* Number laboratories by year end S. pneumoniae %Penicillin NS* of which: %HLR %Int %Erythromycin R* %Penicillin NS/Erythromycin R Number laboratories by year end P. aeruginosa %Piperacillin/tazobactam R* %Ceftazidime R* %Imipenem/meropenem R* %Ciprofloxacin R* %Gentamicin R* %MDR* Number laboratories by year end 41 Acinetobacter spp. 91 %Ciprofloxacin R* 3 %Gentamicin R* No data No data No data No data No data No data No data %Gentamicin/Amikacin/Tobramycin R* 1 %Carbapenem 1 R* 4 %MDR* Changes to previous reports are highlighted in RED Highest annual proportion reported in 213 R, Resistant; NS, Non Susceptible [includes isolates with intermediate (Int) and high level resistance (HLR)] Lowest annual proportion reported in 213 MRSA, Meticillin Resistant S. aureus ; VREfm, Vancomycin Resistant E. faecium; VREfa, Vancomycin Resistant E. faecalis HLG, High Level Gentamicin; 3GC, 3rd Generation Cephalosporin (includes cefotaxime, ceftriaxone, ceftazidime and cefpodoxime); ESBL, Extended Spectrum Beta Lactamase; MDR, Multi Drug Resistant * Not all isolates tested; ** 213 data provisional to the end of Q4 In 21, 3 laboratories stopped processing blood cultures, however coverage of acute hospitals remained at 1%; In Q3 211, one addi onal laboratory started repor ng 1 Carbapenems include imipenem, meropenem and ertapenem 2 MDRKP, MDR K. pneumoniae phenotype (ESBL producer plus non susceptibility to Ciprofloxacin and Gentamicin) OR carbapenemase producer (e.g. KPC, OXA 48) Page 2 of 18

3 Table 2. Summary of EARS Net data by pathogen and quarter, Q1 212 to Q4 213 (data correct as of 3/3/214) Pathogen E. coli Quarter 212Q1 212Q2 212Q3 212Q4 213Q1 213Q2 213Q3 213Q %Ampicillin R* %3GC R* %ESBL producers* %Ciprofloxacin R* %Gentamicin R* %Gentamicin/Amikacin/Tobramycin R* %Carbapenem 1 R* %MDR* S. aureus Number Meticillin R (or MRSA) %Meticillin R (or MRSA) E. faecium %Ampicillin R* %Vancomycin R (VREfm) %HLG R* %MDR* E. faecalis %Ampicillin R* %Vancomycin R (VREfa) %HLG R* K. pneumoniae %Ampicillin R* %3GC R* %ESBL producers* %Ciprofloxacin R* %Gentamicin R* %Gentamicin/Amikacin/Tobramycin R* S. pneumoniae P. aeruginosa Acinetobacter spp. %Carbapenem 1 R* %MDRKP 2 * %MDR* %Penicillin NS* of which: %HLR %Int %Erythromycin R* %Penicillin NS/Erythromycin R %Piperacillin/tazobactam R* %Ceftazidime R* %Imipenem/meropenem R* %Ciprofloxacin R* %Gentamicin R* %MDR* %Ciprofloxacin R* %Gentamicin R* No data No data No data No data %Gentamicin/Amikacin/Tobramycin R* 3 %Carbapenem 1 R* %MDR* MRSA, Meticillin Resistant S. aureus ; VREfm, Vancomycin Resistant E. faecium; VREfa, Vancomycin Resistant E. faecalis R, Resistant; NS, Non Susceptible [includes isolates with intermediate (Int) and high level resistance (HLR)] HLG, High Level Gentamicin; 3GC, 3rd Generation Cephalosporin (includes cefotaxime, ceftriaxone, ceftazidime and cefpodoxime); ESBL, Extended Spectrum Beta Lactamase; MDR, Multi Drug Resistant * Not all isolates tested 1 Carbapenems include imipenem, meropenem and ertapenem 2 MDRKP, MDR K. pneumoniae phenotype (ESBL producer plus non susceptibility to Ciprofloxacin and Gentamicin) OR carbapenemase producer (e.g. KPC, OXA 48) Page 3 of 18

4 Table 3. Summary of EARS Net data by pathogen and HSE Area, 213 (data correct as of 3/3/214) Pathogen E. coli S. aureus E. faecium E. faecalis K. pneumoniae S. pneumoniae P. aeruginosa Acinetobacter spp. HSE Area Dublin/Mid Leinster Dublin/North East South West %ESBL producers* %MDR* Number Meticillin R (or MRSA) %Meticillin R (or MRSA) %Vancomycin R (VREfm) %MDR* %Vancomycin R (VREfa) %ESBL producers* %Carbapenem 1 R* %MDRKP 2 * %MDR* %Penicillin NS* %Penicillin NS/Erythromycin R Changes to previous reports are highlighted in RED %MDR* %MDR*. MRSA, Meticillin Resistant S. aureus; VREfm, Vancomycin Resistant E. faecium ; VREfa, Vancomycin Resistant E. faecalis R, Resistant; NS, Non Susceptible (includes isolates with intermediate and high level resistance) ESBL, Extended Spectrum Beta Lactamase; MDR, Multi Drug Resistant * Not all isolates tested 1 Carbapenems include imipenem, meropenem and ertapenem 2 MDRKP, MDR K. pneumoniae phenotype (ESBL producer plus non susceptibility to Ciprofloxacin and Gentamicin) OR carbapenemase producer (e.g. KPC, OXA 48) Page 4 of 18 National

5 Invasive E. coli infections Number Invasive E. coli cases: 2,526 Number ESBL-positive E. coli cases: 262 (of 2,51 tested) % ESBL-positive E. coli: 1.4% Number MDR E. coli cases: 37 (of 2,52 tested) % MDR E. coli: 14.7% Commentary: Number and % ESBL-positive and MDR E. coli are the highest since surveillance began in 22 ESBL-positive and MDR E. coli have been increasing since 24 E. coli data, 213 (Q1 4) 2,526 isolates (2,521 from blood and 5 from CSF) 32 (12.7%) of2,524 isolates were resistant to 3GCs, of which 254 were ESBL positive and 64 were ESBL negative; 638 (25.3%) of 2,522 were ciprofloxacin resistant; and 245 (9.7%) of 2,524 were gentamicin resistant [323 (12.8%) of 2,526 were aminoglycoside resistant (i.e. resistant to gentamicin, tobramycin or amikacin)] 262 (1.4%) of 2,51 isolates were ESBL positive 2 (.1%) of 2,52 isolates were resistant to carbapenems (imipenem or meropenem), neither of which was carbapenemase producer. It is probable that the resistance mechanism in these was due to a combination of ESBL production (both were positive) and porin loss 371 (14.7%) of 2,25 isolates from 48 hospitals/institutions were MDR, i.e. resistant to 3 or more of the required antibiotic classes [ampicillin, 3GCs (e.g. cefotaxime, ceftazidime), fluoroquinolones (e.g. ciprofloxacin) and aminoglycosides (as above)]: o 149 with resistance to ampicillin, 3GCs, ciprofloxacin and aminoglycosides (136 ESBL positive, 17 negative) o 15 with resistance to ampicillin, 3GCs and ciprofloxacin (87 ESBL positive, 17 negative) o 7 with resistance to ampicillin, 3GCs and aminoglycosides (5 ESBL positive, 2 negative) o 11 with resistance to ampicillin, ciprofloxacin and aminoglycosides (one ESBL positive, 18 negative) * Total E. coli %3GC R %ESBL+ve 16% 14% 12% 1% 8% 6% 4% 2% % %3GC R/ESBL+ve Figure 1. Trends for ESBL producing E. coli total numbers of ESBL producers and percentage positivity (with percentage 3GC resistance for comparison) with 9CIs * Data for 213 are provisional to the end of Q4 Figure 2. Distribution of 3 rd -generation cephalosporin-resistant E. coli in EARS-Net countries in 212 Map obtained from ECDC on 6/3/214: base/pages/map reports.aspx Page 5 of 18

6 E. coli trends in resistance Resistance to 3GCs increased from 2.6% in 24 to 12.7% in 213 (to the end of Q4), while the proportion of ESBL producers increased from 1.1% to 1.4% over the same period. Both are provisionally the highest annual proportions reported to date (Figure 1) Between 29 and 213 (to the end of Q4): o resistance to ciprofloxacin increased from 22.3% to 25.3% while resistance to aminoglycosides increased from 9.3% to 12.8%, both of which are the highest annual proportions reported to date (Figure 3) o MDR isolates increased from 1.4% to 14.7%, the highest annual proportion reported to date (Figure 4) 3 3% 3 18% % 14% % 1% %Resistance % 1% 8% 6% 4% 2% %MDR ECO * Total E. coli %3GC R %FQREC %GEN R %GEN/TOB/AMK R Figure 3. Trends for E. coli total numbers of E. coli and percentage resistance to 3GCs, ciprofloxacin/ofloxacin (CIP/OFX), gentamicin (GEN) and gentamicin/tobramycin /amikacin (GEN/TOB/AMK) with 9CIs * Data for 213 are provisional to the end of Q4 % * Total E. coli tested for MDR MDR ECO %MDR Figure 4. Trends for Multi Drug Resistant (MDR) E. coli total numbers of MDR E. coli and percentage MDR with 9CIs * Data for 213 are provisional to the end of Q4 % Page 6 of 18

7 S. aureus bloodstream infections Number S. aureus BSI cases: 1,94 Number MRSA cases: 222 % MRSA: 2.3% Commentary: Number and % MRSA are the lowest since surveillance began in 1999 MRSA has been decreasing since 26 S. aureus data, 213 (Q1 4) 1,94 isolates, of which 222 (2.3%) were MRSA 91 (43.8%) of 28 MRSA isolates were fusidic acid resistant compared with 12 (15.%) of 799 MSSA isolates Among MRSA, 3 isolates (1.) were resistant to rifampicin (n=21). No resistance was detected to linezolid (n=22) No isolates with reduced susceptibility to glycopeptides were detected by the National MRSA Reference Laboratory S. aureus trends in resistance The annual trends indicate the proportion of MRSA in Ireland decreased from 41.9% in 26 to 22.8% in 212 and 2.3% in 213 (to the end of Q4), which is provisionally the lowest annual proportion since surveillance began in 1999 (Figure 5) Between 26 (when the number of MRSA bloodstream infections peaked) and 213, the overall MRSA numbers decreased by 63% For the latest data on S. aureus/mrsa by acute hospital in Ireland, see: Z/MicrobiologyAntimicrobialResistance/EuropeanAntimicrobialResistanceSurveillanceSystemEARSS/ReferenceandEdu cationalresourcematerial/saureusmrsa/latestsaureusmrsadata/ * Total S. aureus MRSA %MRSA 4 4% 3 3% 2% 1% % %MRSA Figure 5. Trends for S. aureus total numbers of S. aureus/mrsa and percentage MRSA with 9CIs * Data for 213 are provisional to the end of Q4 Figure 6. Distribution of MRSA in EARS-Net countries in 212 Map obtained from ECDC on 6/3/214: database/pages/map_reports.aspx Page 7 of 18

8 E. faecium bloodstream infections Number E. faecium BSI cases: 49 Number vancomycin-resistant E. faecium, or VREfm, cases: 176 (of 48 tested) % VREfm: 43.1% Commentary: Ireland has the highest proportion of E. faecium that are VREfm in Europe and was the only country reporting a proportion in excess of in 212 (Figure 8) E. faecium data, 213 (Q1 4) 49 isolates 281 (68.7%) of 49 isolates were from the 9 tertiary/teaching hospitals 176 (43.1%) of 48 were resistant to vancomycin (i.e. vancomycin resistant E. faecium or VREfm) and 165 (41.4%) of 399 isolates were resistant to high level gentamicin (HLG) 78 (19.6%) of 398 isolates from 8 hospitals were MDR, defined as resistant to ampicillin, HLG and vancomycin E. faecium trends in resistance The annual trends indicate that the proportion of VREfm increased from 33.4% in 27 to 45.4% in 212, which is the highest annual proportion since surveillance began in 22 (Figure 7). In 213 (to the end of Q4), the proportion of VRE decreased to 43.1% Ireland has the highest proportion of VREfm in Europe. In 212, it was the only country to report a proportion in excess of (Figure 9) The proportion of MDR isolates decreased from 26.7% (the highest proportion reported to date) in 29 to 19.6% in 213 (to the end of Q4) (Figure 1) * Total E. faecium %VREfm %HLGR Efm 7% 6% 4% 3% 2% 1% % %Resistance Figure 7. Trends for E. faecium total numbers of E. faecium and percentage resistance to high level gentamicin (HLGR Efm) and vancomycin (VREfm) with 9CIs * Data for 213 are provisional to the end of Q4 Figure 8. Distribution of vancomycin-resistant E. faecium (VREfm) in EARS-Net countries in 212 Map obtained from ECDC on 6/3/214: database/pages/map_reports.aspx Page 8 of 18

9 % 2% 1% %MDR Figure 9. Distribution of high-level gentamicin-resistant E. faecium (HLGR-Efm) in EARS-Net countries in 212 Map obtained from ECDC on 6/3/214: database/pages/map_reports.aspx * Total E. faecium tested for MDR MDR EFM %MDR EFM Figure 1. Trends for Multi Drug Resistant (MDR) E. faecium total numbers of MDR E. faecium and percentage MDR with 9CIs * Data for 213 are provisional to the end of Q4 % Page 9 of 18

10 E. faecalis bloodstream infections Number E. faecalis BSI cases: 336 Number vancomycin-resistant E. faecalis, or VREfa, cases: % VREfa: 7 (of 334 tested) 2.1% Commentary: Ireland had the highest proportion (3.%) of E. faecalis that are VREfa in Europe in 212 E. faecalis data, 213 (Q1 4) 336 isolates 7 (2.1%) of 334 were resistant to vancomycin (i.e. vancomycin resistant E. faecalis or VREfa), 17 (33.) of 319 isolates were resistant to HLG and 9 of 98 were resistant to ampicillin (Note: resistance to ampicillin among E. faecalis is an unusual finding) E. faecalis trends in resistance The numbers and proportions of VREfa isolates have fluctuated over the years (Figure 11). In 211, 4.9% (n=13) of isolates were VREfa, which was the highest proportion since surveillance began in 22 Although the proportion of VREfa is low, Ireland still has one of the highest proportions among countries reporting to EARS Net. In 212, Ireland had the highest proportion (3.%) in Europe (Figure 12) * Total E. faecalis tested for VAN VREfa %VREfa 12% 1% 8% 6% 4% 2% % 2% 4% 6% %VREfm Figure 11. Trends for vancomycin resistant E. faecalis (VREfa) total numbers of VREfa and percentage VREfa with 9CIs * Data for 213 are provisional to the end of Q4 Figure 12. Distribution of vancomycin-resistant E. faecalis (VREfa) in EARS-Net countries in 212 Map obtained from ECDC on 6/3/214: database/pages/map_reports.aspx Page 1 of 18

11 Invasive K. pneumoniae infections Number Invasive K. pneumoniae cases: 326 Number ESBL-positive K. pneumoniae cases: 6 % ESBL-positive K. pneumoniae: 18.4% Commentary: Number and % ESBL-positive are the highest since surveillance began in 26 ESBL-positive K. pneumoniae have increased significantly over the past 3 years K. pneumoniae data, 213 (Q1 4) 326 isolates (323 from blood and 3 from CSF) 69 (21.2%) of 325 isolates were resistant to 3GCs, 6 of which were ESBL positive and 9 were ESBL negative; 68 (2.9%) of 325 were ciprofloxacin resistant; and 55 (16.9%) of 325 were gentamicin resistant [57 (17.) of 326 were aminoglycoside resistant (i.e. resistant to gentamicin, tobramycin or amikacin)] 3 (.9%) of 325 isolates were susceptible to ampicillin (Note: ampicillin susceptibility among K. pneumoniae is unusual) 62 (19.1%) of 325 isolates from 17 hospitals were MDR (defined as resistance to 2 or more of the key antibiotics required by the EARS Net protocol): o 42 with resistance to ampicillin, 3GCs, ciprofloxacin and aminoglycosides (38 ESBL positive, 4 negative) o 7 with resistance to ampicillin, 3GCs and ciprofloxacin (all ESBL positive) o 6 with resistance to ampicillin, 3GCs and aminoglycosides (5 ESBL positive, one negative) o 6 with resistance to ampicillin, ciprofloxacin and aminoglycosides (all ESBL negative) Of 326 isolates, 6 (18.4%) were found to produce ESBLs 4 carbapenem resistant enterobacteriaceae (CRE) isolates were reported from 326 isolates, 2 of which were confirmed carbapenemase producers (both OXA 48) and also resistant to ampicillin, 3GCs, ciprofloxacin and aminoglycosides (ESBL negative) (i.e. MDR). No carbapenemase was detected in the other 2 isolates and it is probable that the resistance mechanism in these was due to a combination of ESBL production (both were positive) and porin loss K. pneumoniae trends in resistance Between 21 and 213 (to the end of Q4), resistance to ciprofloxacin [2.9% (21, 1.)], gentamicin [16.9% (21, 6.8%)] and aminoglycosides [17. (21, 7.1%)] and ESBL producers [18.4% (21, 5.%)] (Figures 13 and 15) increased. Between 211 and 213 (to the end of Q4), resistance to 3GCs [21.2% (211, 8.%)] also increased (Figure 13). All of these are provisionally the highest annual proportions reported to date In 212, many Eastern and Southern European countries reported proportions in excess of to EARS Net (Figure 14). Ireland had one of the lowest proportions in 212, but the provisional data for 213 indicate that proportion of 3GC resistance has almost doubled here over the past year Between 21 and 213 (to the end of Q4), the proportion of MDR increased from 8.% to 19.1%, which is provisionally the highest annual proportions reported to date (Figure 16) In 213, 2 carbapenemase producing CRE (CPE) isolates (both OXA 48) were reported. In 211, there were 4 CPE isolates of K. pneumoniae, which were the first reports of invasive CRE due to carbapenemases in Ireland (Figure 17) Carbapenem resistance is already a major problem in Greece and Italy, with proportions of 62% and 31%, respectively, in 212 (Figure 18) Among isolates that belonged to a particular MDR profile, or MDRKP phenotype (i.e. were simultaneously NON SUSCEPTIBLE to ciprofloxacin and gentamicin AND ESBL producers), 2 major clonal groups have been identified (Source: Antibiotic Resistance and Microbial Ecology (ARME) Laboratory, National University Ireland, Galway). In 213, 38 isolates (of 325, or 1.7%) reported to EARS Net were identified with this phenotype compared with 18 (of 342, or 5.3%) in 212 and 1 (of 34, or 3.3%) in 211 (Figure 19) Page 11 of 18

12 * Total KPN %3GC R %ESBL+ve 3% 2% 1% % %3GC R/ESBL+ve Figure 13. Trends for ESBL producing K. pneumoniae total numbers of ESBL producers and percentage positivity (with percentage 3GC resistance for comparison) with 9CIs * Data for 213 are provisional to the end of Q4; the numbers of participating laboratories by year end are indicated above the bars Figure 14. Distribution of 3GC resistant K. pneumoniae in EARS-Net countries in 212 Map obtained from ECDC on 6/3/214: abase/pages/map_reports.aspx % % 1% %Resistance % 1% %MDR * Total KPN %3GC R %CIP/OFX R %GEN/TOB/AMK R %GEN R Figure 15. Trends for K. pneumoniae total numbers of K. pneumoniae and percentage resistance to 3GCs, ciprofloxacin/ofloxacin (CIP/OFX), gentamicin (GEN) and gentamicin/tobramycin/amikacin (GEN/TOB/AMK) with 9CIs * Data for 213 are provisional to the end of Q4; the numbers of participating laboratories by year end are indicated above the bars % * Total KPN tested for MDR MDR KPN %MDR Figure 16. Trends for Multi Drug Resistant K. pneumoniae total numbers of MDR K. pneumoniae and percentage MDR with 9CIs * Data for 213 are provisional to the end of Q4; the numbers of participating laboratories by year end are indicated above the bars % % 3% 2% 1% %CBP R * Total K. pneumoniae tested for CBP CBP R KPN %CBP R Figure 17. Trends for carbapenem (CBP) resistant K. pneumoniae total numbers and percentage resistance to CBP with 9CIs * Data for 213 are provisional to the end of Q4; the numbers of participating laboratories by year end are indicated above the bars Carbapenems include imipenem, meropenem and ertapenem % Page 12 of 18 Figure 18. Distribution of carbapenem resistant K. pneumoniae in EARS-Net countries in 212 Map obtained from ECDC on 6/3/214: abase/pages/map_reports.aspx

13 Number of cases * 14% 12% 1% 8% 6% 4% 2% % % of all cases No. MDRKP phenotype %MDRKP phenotype Figure 19. Trends for K. pneumoniae isolates with the MDRKP phenotype (simultaneously NON SUSCEPTIBLE to ciprofloxacin and gentamicin AND ESBL producers) numbers and percentage with MDRKP phenotype with 9CIs * Data for 213 are provisional to the end of Q4 Page 13 of 18

14 Invasive S. pneumoniae infections Number invasive S. pneumoniae cases: 311 Number penicillin-non-susceptible S. pneumoniae, or PNSP: % PNSP: 64 (of 38 tested) 2.8% Number S. pneumoniae cases with non-susceptibility to both penicillin and erythromycin ( Pen/Ery-NS): 39 (of 293 tested) % Pen/Ery-NS S. pneumoniae: 13.3% Commentary: The % PNSP in 213 was the 2 nd highest proportion reported since surveillance began in 1999 Ireland had one of the highest proportions of PNSP in Europe in 212 S. pneumoniae data, 213 (Q1 4) 311 isolates (34 from blood and 7 from CSF) CLSI guidelines distinguish between non meningitis [Susceptible (S) 2 mg/l, Intermediate (I) 4 mg/l, Resistant (R) 8 mg/l] and meningitis breakpoints (S.6 mg/l, R.12 mg/l) for iv/parenteral penicillin and recommend that blood isolates should be reported using both sets of breakpoints. EUCAST guidelines distinguish between non meningitis [Susceptible (S).6 mg/l, Intermediate (I).12 2 mg/l, Resistant (R) 4 mg/l] and meningitis breakpoints (S.6 mg/l, R.12 mg/l) for benzylpenicillin EARSS previously recommended using the old CLSI breakpoints (S.6 mg/l, I mg/l, R 2 mg/l), corresponding to the new oral breakpoints, for surveillance purposes, to avoid confusion with interpretation of historic data and until a consensus approach could be agreed. The EUCAST non meningitis breakpoints (S.6 mg/l, I.12 2 mg/l, R 4 mg/l) are very similar to these, hence to facilitate a more meaningful analysis of the data, the oral breakpoints are used for the 14 laboratories still following CLSI (accounting for 33% of S. pneumoniae isolates and 33% of all EARS Net isolates reported in Q4 213) and the meningitis breakpoints for the 27 laboratories following EUCAST (accounting for 67% of S. pneumoniae, as well as for 67% of all EARS Net isolates) ***Penicillin and cefotaxime/ceftriaxone MICs should be submitted on all pneumococcal isolates*** 64 (2.8%) of 38 isolates were PNSP (defined as having a penicillin MIC of.12 mg/l) (Note: 3 additional isolates were reported as penicillin susceptible but with no MICs) and 54 (17.9%) of 32 isolates were resistant to erythromycin Penicillin and cefotaxime/ceftriaxone MICs were available for 64 and 62 PNSP isolates, respectively 7 isolates were high level resistant and 57 were intermediately resistant to penicillin. Ten PNSP isolates (3 high level resistant and 7 intermediately resistant) were non susceptible to cefotaxime Erythromycin resistance was reported in 39 PNSP (6 high level resistant and 33 intermediately resistant) isolates and 12 PSSP isolates For 213, 21 (64.6%) of 311 pneumococcal isolates reported were referred to RCSI/Temple St for capsular serotyping (using a combination of multiplex PCR and conventional serological methods) (Note: no serotyping data were available for Q4 213 isolates at the time of this report). Serotype coverage among the target population for each vaccine, <2 years for PCV13 and 65 years for PPV23, was 3% (3 of 1 isolates) and 68% (7 of 13 isolates), respectively. The most common serotypes identified were 7F (n=34), 19A (n=23), 3 (n=13) and 22F (n=12) representing 41% of all isolates typed S. pneumoniae trends in resistance The annual trends indicate that the proportion of PNSP increased from 18.2% in 29 to 2.8% in 213 (to the end of Q4), which is provisionally the 2 nd highest annual proportion since surveillance began (Figure 2) In 212, Ireland had the 4 th highest proportion of PNSP of countries in Europe reporting over 5 isolates (Figure 21) In 213 (to the end of Q4), the proportion of S. pneumoniae with resistance to erythromycin (17.9%) is provisionally the 2 nd highest annual proportion reported to date (Figure 22) Between 25 and 211, co resistance to penicillin and erythromycin amongst S. pneumoniae isolates increased significantly from 3.2% to 13.8%, which was the highest proportion reported to date (Figure 23). In 213, the proportion remains at a high level (13.2%) Page 14 of 18

15 % 2% 1% %PNSP % * Total S.pneumoniae PNSP %I %HLR %PNSP Figure 2. Trends for S. pneumoniae total numbers of S. pneumoniae/penicillin Non Susceptible S. pneumoniae (PNSP) and percentage PNSP [penicillin intermediate (Pen I) and high level resistant (Pen HLR)] with 9CIs * Data for 213 are provisional to the end of Q4 Figure 21. Distribution of penicillin non-susceptible S. pneumoniae (PNSP) in EARS-Net countries in 212 Map obtained from ECDC on 6/3/214: /database/pages/map_reports.aspx 5 5 2% % 4 2% 4 16% % %ENSP % 12% 1% 8% 6% %PEN/ERY R 1 1 4% 5 5 2% % % * * Total S.pneumoniae ENSP %ENSP Total S.pneumoniae Pen/Ery NS %Pen/Ery NS Figure 22. Trends for S. pneumoniae total numbers of S. pneumoniae/erythromycin Non Susceptible S. pneumoniae (ENSP) and percentage ENSP with 9CIs * Data for 213 are provisional to the end of Q4 Figure 23. Trends for S. pneumoniae total numbers of S. pneumoniae/co resistant to penicillin and erythromycin (Pen/Ery NS) and percentage Pen/Ery NS with 9CIs * Data for 213 are provisional to the end of Q4 Page 15 of 18

16 Invasive P. aeruginosa infections Number Invasive P. aeruginosa cases: 27 Number MDR cases: 262 (of 2,51 tested) % MDR: 9.4% Commentary: Resistance to all 5 key antibiotic classes decreased in 213 The highest number and proportion of isolates with resistance to piperacillintazobactam, ceftazidime and imipenem/meropenem were reported in 212 P. aeruginosa data, 213 (Q1 4) 27 isolates (26 from blood and one from CSF) 31 (15.2%) of 24 isolates were resistant to piperacillin tazobactam; 22 (1.7%) of 26 were resistant to ceftazidime; 25 (12.1%) of 26 were resistant to imipenem or meropenem; 32 (15.) of 27 was resistant to ciprofloxacin; and 24 (11.6%) of 27 were resistant to gentamicin [no additional isolates were resistant to the other aminoglycosides (amikacin or tobramycin)] 19 (1.4%) of 23 isolates from 13 hospitals were MDR including: o 3 with resistance to all 5 key antibiotics classes o 1 with resistance to 4 of the 5 key antibiotics classes o 6 with resistance to 3 of the 5 key antibiotics classes P. aeruginosa trends in resistance In 213 (to the end of Q4), the proportion of isolates with resistance to all 5 key antibiotic classes decreased compared to 212 (Figures 24 and 25) In 212, resistance to piperacillin tazobactam (17.4%), ceftazidime (15.2%) and imipenem/meropenem (19.6%) were the highest annual proportions reported for these to date (Figure 24) The proportion of MDR (13.%) in 212 was the highest annual proportion reported to date (Figure 26) % % % 1% %Resistance % 1% %Resistance 5 5 % * Total PAE %PIP/TZP R %CAZ R %IPM/MEM R * Total PAE %GEN R %CIP/OFX R % Figure 24. Trends for P. aeruginosa total numbers of P. aeruginosa and percentage resistance to piperacillintazobactam (PIP/TZP), ceftazidime (CAZ) and imipenem/ meropenem (IPM/MEM) with 9CIs * Data for 213 are provisional to the end of Q4; the numbers of participating laboratories by year end are indicated above the bars Figure 25. Trends for P. aeruginosa total numbers of P. aeruginosa and percentage resistance to ciprofloxacin/ ofloxacin (CIP/OFX) and gentamicin (GEN) with 9CIs *Data for 213 are provisional to the end of Q4; the numbers of participating laboratories by year end are indicated above the bars Page 16 of 18

17 * Total P. aeruginosa tested for MDR MDR %MDR Figure 26. Trends for P. aeruginosa total numbers of P. aeruginosa and percentage resistance to piperacillintazobactam (PIP/TZP), ceftazidime (CAZ) and imipenem/ meropenem (IPM/MEM) with 9CIs * Data for 213 are provisional to the end of Q4; the numbers of participating laboratories by year end are indicated above the bars 2% 18% 16% 14% 12% 1% 8% 6% 4% 2% % %MDR Figure 27. Distribution of carbapenem resistant P. aeruginosa in EARS-Net countries in 212 Map obtained from ECDC on 6/3/214: /database/pages/map_reports.aspx Page 17 of 18

18 Invasive Acinetobacter spp. infections Number Invasive Acinetobacter spp. cases: 91 Commentary: Low levels of resistance in Ireland but interpret with caution as low numbers of cases Acinetobacter spp data, 213 (Q1 4) 91 isolates (low numbers: interpret with caution) from 28 hospitals/institutions in all HSE Areas 49 (53%) of 91 isolates were from the 5 tertiary/teaching hospitals 3 (3%) of 89 were resistant to ciprofloxacin (fluoroquinolones), one (1%) of 89 isolates were resistant to aminoglycosides and 3 (4%) of 86 were resistant to carbapenems No isolates were MDR Page 18 of 18

9.5 Antimicrobial Resistance

9.5 Antimicrobial Resistance 9.5 Antimicrobial Resistance Key Points In 215, there was a slight reduction in coverage of the Irish population by EARS-Net versus 214, from 1% to 97% There were 2,697 reports of invasive Escherichia

More information

9.4 Antimicrobial Resistance

9.4 Antimicrobial Resistance 9.4 Antimicrobial Resistance a) Key Pathogens causing Bloodstream Infections 2016 Summary Estimated 99% coverage of the Irish population versus 97% in 2015 There were 3,057 reports of invasive E. coli

More information

How is Ireland performing on antibiotic prescribing?

How is Ireland performing on antibiotic prescribing? European Antibiotic Awareness Campaign 2016 November Webinar Series on Antibiotic Prescribing How is Ireland performing on antibiotic prescribing? Dr Rob Cunney National Clinical Lead HCAI AMR Clinical

More information

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory

More information

Summary of the latest data on antibiotic resistance in the European Union

Summary of the latest data on antibiotic resistance in the European Union Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network

More information

EUCAST recommended strains for internal quality control

EUCAST recommended strains for internal quality control EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC

More information

European Committee on Antimicrobial Susceptibility Testing

European Committee on Antimicrobial Susceptibility Testing European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The

More information

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine 2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose

More information

THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS

THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be

More information

European Committee on Antimicrobial Susceptibility Testing

European Committee on Antimicrobial Susceptibility Testing European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01

More information

RCH antibiotic susceptibility data

RCH antibiotic susceptibility data RCH antibiotic susceptibility data The following represent RCH antibiotic susceptibility data from 2008. This data is used to inform antibiotic guidelines used at RCH. The data includes all microbiological

More information

Routine internal quality control as recommended by EUCAST Version 3.1, valid from

Routine internal quality control as recommended by EUCAST Version 3.1, valid from Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus

More information

Antimicrobial Susceptibility Testing: Advanced Course

Antimicrobial Susceptibility Testing: Advanced Course Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to

More information

Understanding the Hospital Antibiogram

Understanding the Hospital Antibiogram Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital

More information

TECHNICAL REPORT External quality assessment of laboratory performance European Antimicrobial Resistance Surveillance Network (EARS-Net), 2017

TECHNICAL REPORT External quality assessment of laboratory performance European Antimicrobial Resistance Surveillance Network (EARS-Net), 2017 TECHNICAL REPORT External quality assessment of laboratory performance European Antimicrobial Resistance Surveillance Network (EARS-Net), 2017 www.ecdc.europa.eu ECDC TECHNICAL REPORT External quality

More information

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University

More information

MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC

MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical

More information

Antimicrobial Resistance Surveillance from sentinel public hospitals, South Africa, 2013

Antimicrobial Resistance Surveillance from sentinel public hospitals, South Africa, 2013 Antimicrobial Resistance Surveillance from sentinel public s, South Africa, 213 Authors: Olga Perovic 1,2, Melony Fortuin-de Smidt 1, and Verushka Chetty 1 1 National Institute for Communicable Diseases

More information

Antibacterial Resistance In Wales

Antibacterial Resistance In Wales A Report from Public Health Wales Antimicrobial Resistance Programme Surveillance Unit: Antibacterial Resistance In Wales 2005-2012 Authors: Maggie Heginbothom Robin Howe & Catherine Thomas Version: 1

More information

Intrinsic, implied and default resistance

Intrinsic, implied and default resistance Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been

More information

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016 Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate

More information

2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services

2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services 2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens

More information

National Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults

National Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014

More information

ANTIMICROBIAL RESISTANCE SURVEILLANCE FROM SENTINEL PUBLIC HOSPITALS, SOUTH AFRICA, 2014

ANTIMICROBIAL RESISTANCE SURVEILLANCE FROM SENTINEL PUBLIC HOSPITALS, SOUTH AFRICA, 2014 ANTIMICROBIAL RESISTANCE SURVEILLANCE FROM SENTINEL PUBLIC HOSPITALS, SOUTH AFRICA, 2014 Olga Perovic, 1,2 Verushka Chetty 1 & Samantha Iyaloo 1 1 National Institute for Communicable Diseases, NHLS 2 Department

More information

Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland

Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the

More information

2015 Antibiotic Susceptibility Report

2015 Antibiotic Susceptibility Report Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens

More information

2016 Antibiotic Susceptibility Report

2016 Antibiotic Susceptibility Report Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates

More information

Concise Antibiogram Toolkit Background

Concise Antibiogram Toolkit Background Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions

More information

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose 2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility

More information

BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)

BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance

More information

2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital

2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital 2010 ANTIBIOGRAM University of Alberta Hospital and the Stollery Children s Hospital Medical Microbiology Department of Laboratory Medicine and Pathology Table of Contents Page Introduction..... 2 Antibiogram

More information

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose 2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility

More information

Antimicrobial resistance (EARS-Net)

Antimicrobial resistance (EARS-Net) SURVEILLANCE REPORT Annual Epidemiological Report for 2014 Antimicrobial resistance (EARS-Net) Key facts Over the last four years (2011 to 2014), the percentages of Klebsiella pneumoniae resistant to fluoroquinolones,

More information

Antimicrobial Stewardship Strategy: Antibiograms

Antimicrobial Stewardship Strategy: Antibiograms Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide

More information

GENERAL NOTES: 2016 site of infection type of organism location of the patient

GENERAL NOTES: 2016 site of infection type of organism location of the patient GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007

More information

جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی

جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه

More information

Antibacterial Resistance In Wales

Antibacterial Resistance In Wales A Report from Public Health Wales Antimicrobial Resistance Programme Surveillance Unit: Antibacterial Resistance In Wales 2005-2013 Authors: Maggie Heginbothom and Robin Howe Version: 1 Antibacterial Resistance

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Quality Assurance of antimicrobial susceptibility testing Derek Brown EUCAST Scientific Secretary ESCMID Postgraduate Education Course, Linz, 17 September 2014 Quality Assurance The total process by which

More information

Mechanism of antibiotic resistance

Mechanism of antibiotic resistance Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance

More information

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria

More information

03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline

03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline Infection Prevention and Control A Foundation Course 2014 What is healthcare-associated infection (HCAI), antimicrobial resistance (AMR) and multi-drug resistant organisms (MDROs)? Why we should be worried?

More information

5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO)

5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO) Multidrug Resistant Organisms (MDROs) Kasturi Shrestha, M.D. 05/11/2018 Objectives Define a multi-drug resistant organism (MDRO) Identify most challenging MDROs in healthcare Identify reasons for health

More information

EARS-Net Belgium Data call for 2016: Instructions for participating laboratories, including data definition. (version 4, 20/3/2017)

EARS-Net Belgium Data call for 2016: Instructions for participating laboratories, including data definition. (version 4, 20/3/2017) EARS-Net Belgium Data call for 2016: Instructions for participating laboratories, including data definition. (version 4, 20/3/2017) Questions on this document can be directed towards: Karl Mertens Scientific

More information

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to

More information

2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital

2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital 2009 ANTIBIOGRAM University of Alberta Hospital and the Stollery Childrens Hospital Division of Medical Microbiology Department of Laboratory Medicine and Pathology 2 Table of Contents Page Introduction.....

More information

Antibacterial Resistance in Wales

Antibacterial Resistance in Wales Antibacterial Resistance in Wales 2006-2015 June 2016 Microbiology Division, Public Health Wales Table of Contents Table of Contents... 1 Section 1: Introduction... 2 Section 2: Key points of interest...

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXVII NUMBER 6 July 2012 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine B. Dowell SM, MLS (ASCP); Sarah K. Parker, MD; James K. Todd, MD Each year the Children s Hospital Colorado

More information

Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC

Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant

More information

Antimicrobial Resistance Trends in the Province of British Columbia

Antimicrobial Resistance Trends in the Province of British Columbia 655 West 12th Avenue Vancouver, BC V5Z 4R4 Tel 604.707.2443 Fax 604.707.2441 www.bccdc.ca Antimicrobial Resistance Trends in the Province of British Columbia 2013 Prepared by the Do Bugs Need Drugs? Program

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.

More information

What s next in the antibiotic pipeline?

What s next in the antibiotic pipeline? What s next in the antibiotic pipeline? Jennifer Tieu, Pharm.D., BCPS Clinical Pearls OSHP Spring Meeting Mercy Hospital April 13, 2018 Objective 2 Describe the drug class and mechanism of action of antibiotics

More information

Including data call, instructions for participating laboratories, data definition, reporting procedure.

Including data call, instructions for participating laboratories, data definition, reporting procedure. EARS-Net Belgium 2016 - Protocol: Including data call, instructions for participating laboratories, data definition, reporting procedure. (version 7, 6/7/2017) Questions on this document can be directed

More information

Jean-Winoc Decousser 1*, Paul-Louis Woerther 1, Claude-James Soussy 1, Marguerite Fines-Guyon 2 and Michael J. Dowzicky 3

Jean-Winoc Decousser 1*, Paul-Louis Woerther 1, Claude-James Soussy 1, Marguerite Fines-Guyon 2 and Michael J. Dowzicky 3 Decousser et al. Antimicrobial Resistance and Infection Control (2018) 7:68 https://doi.org/10.1186/s13756-018-0360-y RESEARCH Open Access The Tigecycline Evaluation and Surveillance Trial; assessment

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXXII NUMBER 6 September 2017 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Stacey Hamilton MT SM (ASCP), Samuel Dominguez MD PhD, Sarah Parker MD, and

More information

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Expert rules in susceptibility testing EUCAST-ESGARS-EPASG Educational Workshop Linz, 16 19 September, 2014 Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA

More information

INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS

INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS 1 Research Associate, Drug Utilisation Research Unit, Nelson Mandela University 2 Human Sciences Research Council,

More information

a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.

a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2. AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony

More information

C&W Three-Year Cumulative Antibiogram January 2013 December 2015

C&W Three-Year Cumulative Antibiogram January 2013 December 2015 C&W Three-Year Cumulative Antibiogram January 213 December 215 Division of Microbiology, Virology & Infection Control Department of Pathology & Laboratory Medicine Contents Comments and Limitations...

More information

WHO laboratory-based global survey on multidrug-resistant organisms (MDROs) in health care interim analysis

WHO laboratory-based global survey on multidrug-resistant organisms (MDROs) in health care interim analysis WHO laboratory-based global survey on multidrug-resistant organisms (MDROs) in health care interim analysis Aim: to estimate the burden of MDROs isolated among inpatients in a wide range of health-care

More information

Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges

Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Janet Hindler, MCLS MT(ASCP) UCLA Medical Center jhindler@ucla.edu also working as a consultant with the Association

More information

Appropriate antimicrobial therapy in HAP: What does this mean?

Appropriate antimicrobial therapy in HAP: What does this mean? Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,

More information

Recommendations on Surveillance of Antimicrobial Resistance in Ireland

Recommendations on Surveillance of Antimicrobial Resistance in Ireland Recommendations on Surveillance of Antimicrobial Resistance in Ireland Background This discussion document was prepared by the Antimicrobial Resistance (AMR) Surveillance Working Group, one of a number

More information

What s new in EUCAST methods?

What s new in EUCAST methods? What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests

More information

Antimicrobial Susceptibility Patterns

Antimicrobial Susceptibility Patterns Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department

More information

Report on Antimicrobial Use and Resistance in Humans in 2012

Report on Antimicrobial Use and Resistance in Humans in 2012 Report on Antimicrobial Use and Resistance in Humans in 2012 Acknowledgements This report could not have been compiled without antimicrobial resistance data provided by diagnostic and reference laboratories

More information

Antimicrobial Resistance Strains

Antimicrobial Resistance Strains Antimicrobial Resistance Strains Microbiologics offers a wide range of strains with characterized antimicrobial resistance mechanisms including: Extended-Spectrum β-lactamases (ESBLs) Carbapenamases Vancomycin-Resistant

More information

Main objectives of the EURL EQAS s

Main objectives of the EURL EQAS s EQAS Enterococci, Staphylococci and E. coli EURL workshop, April, 11 Lourdes García Migura Main objectives of the EURL EQAS s To improve the comparability of antimicrobial susceptibility testing (AST)

More information

Mongolia September 2012

Mongolia September 2012 MICROBIOLOGY: bacterial resistance Roßburg / 9.9.22 MVZ DORTMUND - Dr.Eberhard u. Partner - MICROBIOLOGY bacterial resistance control, role of the laboratory MIKROBIOLOGY www.labmed.de / mikro@labmed.de

More information

New Drugs for Bad Bugs- Statewide Antibiogram

New Drugs for Bad Bugs- Statewide Antibiogram New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda

More information

EUCAST Subcommitee for Detection of Resistance Mechanisms (ESDReM)

EUCAST Subcommitee for Detection of Resistance Mechanisms (ESDReM) EUCAST Subcommitee for Detection of Resistance Mechanisms (ESDReM) Christian G. Giske, MD/PhD Chairman of ESDReM Karolinska University Hospital and EUCAST ECCMID, 22 maj 2013 The background Guidance on

More information

Aberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015

Aberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015 Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New

More information

Non-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland,

Non-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland, Non-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland, 2008-2016 Alicia Russell Federation of Infection Societies conference 14 th November 2018 alisia_russell BSAC

More information

Antimicrobial susceptibility

Antimicrobial susceptibility Antimicrobial susceptibility PATTERNS Microbiology Department Canterbury ealth Laboratories and Clinical Pharmacology Department Canterbury District ealth Board March 2011 Contents Preface... Page 1 ANTIMICROBIAL

More information

2015 Antimicrobial Susceptibility Report

2015 Antimicrobial Susceptibility Report Gram negative Sepsis Outcome Programme (GNSOP) 2015 Antimicrobial Susceptibility Report Prepared by A/Professor Thomas Gottlieb Concord Hospital Sydney Jan Bell The University of Adelaide Adelaide On behalf

More information

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018 Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?

More information

Antibacterial Resistance In Wales

Antibacterial Resistance In Wales A Report from Public Health Wales Healthcare Associated Infection, Antimicrobial Resistance & Prescribing Programme (HARP team) Antibacterial Resistance In Wales 2008-2017 Authors: Maggie Heginbothom,

More information

Service Delivery and Safety Department World Health Organization, Headquarters

Service Delivery and Safety Department World Health Organization, Headquarters Service Delivery and Safety Department World Health Organization, Headquarters WHO global (laboratory-based) survey on multidrug-resistant organisms (MDROs) in health care PROJECT SUMMARY Given the important

More information

AMR epidemiological situation: ECDC update

AMR epidemiological situation: ECDC update One Health Network on Antimicrobial Resistance (AMR) AMR epidemiological situation: ECDC update Dominique L. Monnet, on behalf of ECDC Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI)

More information

Surveillance of Antimicrobial Resistance and Healthcare-associated Infections in Europe

Surveillance of Antimicrobial Resistance and Healthcare-associated Infections in Europe Surveillance of Antimicrobial Resistance and Healthcare-associated Infections in Europe Carl Suetens, ECDC Presented by Håkan Hanberger ecdc.europa.eu Message/Questions from C Suetens to Workshop 7, MIE2009

More information

Interpreting Microbiology reports for better Clinical Decisions Interpreting Antibiogrammes

Interpreting Microbiology reports for better Clinical Decisions Interpreting Antibiogrammes Interpreting Microbiology reports for better Clinical Decisions Interpreting Antibiogrammes Prof C. Wattal Hon. Sr. Consultant & Chairman Dept. of Clinical Microbiology Sir Ganga Ram Hospital New Delhi

More information

Available online at ISSN No:

Available online at  ISSN No: Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(4): 36-42 Comparative Evaluation of In-Vitro Doripenem Susceptibility with Other

More information

Antimicrobial Pharmacodynamics

Antimicrobial Pharmacodynamics Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they

More information

ESBL- and carbapenemase-producing microorganisms; state of the art. Laurent POIREL

ESBL- and carbapenemase-producing microorganisms; state of the art. Laurent POIREL ESBL- and carbapenemase-producing microorganisms; state of the art Laurent POIREL Medical and Molecular Microbiology Unit Dept of Medicine University of Fribourg Switzerland INSERM U914 «Emerging Resistance

More information

The UK 5-year AMR Strategy - a brief overview - Dr Berit Muller-Pebody National Infection Service Public Health England

The UK 5-year AMR Strategy - a brief overview - Dr Berit Muller-Pebody National Infection Service Public Health England The UK 5-year AMR Strategy - a brief overview - Dr Berit Muller-Pebody National Infection Service Public Health England Chief Medical Officer - Annual Report 2013 Antimicrobial resistance poses catastrophic

More information

Mike Apley Kansas State University

Mike Apley Kansas State University Mike Apley Kansas State University 2003 - Daptomycin cyclic lipopeptides 2000 - Linezolid - oxazolidinones 1985 Imipenem - carbapenems 1978 - Norfloxacin - fluoroquinolones 1970 Cephalexin - cephalosporins

More information

Streptococcus pneumoniae. Oxacillin 1 µg as screen for beta-lactam resistance

Streptococcus pneumoniae. Oxacillin 1 µg as screen for beta-lactam resistance Streptococcus pneumoniae Oxacillin µg as screen for beta-lactam resistance Version 6. June Streptococcus pneumoniae and zone diameter correlates The following histograms present inhibition zone diameter

More information

Antimicrobial Cycling. Donald E Low University of Toronto

Antimicrobial Cycling. Donald E Low University of Toronto Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and

More information

Taiwan Surveillance of Antimicrobial Resistance (TSAR)

Taiwan Surveillance of Antimicrobial Resistance (TSAR) Taiwan Surveillance of Antimicrobial Resistance (TSAR) 2009 MIRL Symposium July 17, 2009 Tsai-Ling Yang Lauderdale ( ) Microbial Infections Reference Laboratory (MIRL) Division of Infectious Diseases,

More information

Antimicrobial Susceptibility Testing: The Basics

Antimicrobial Susceptibility Testing: The Basics Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories

More information

European Antimicrobial Resistance Surveillance System (EARSS) in Scotland: 2004

European Antimicrobial Resistance Surveillance System (EARSS) in Scotland: 2004 European Antimicrobial Resistance Surveillance System (EARSS) in Scotland: 2004 SECOND ANNUAL REPORT MJ Coyne 1, SJ Dancer 1, G Edwards 2, 3, D Morrison 2. 1 Health Protection Scotland, 2 Scottish MRSA

More information

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics. DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this

More information

Monthly Webinar. Tuesday 12th December 2017, 16:00 Brewing Up a Little Storm. Event number: Audio dial-in (phone):

Monthly Webinar. Tuesday 12th December 2017, 16:00 Brewing Up a Little Storm. Event number: Audio dial-in (phone): Monthly Webinar Tuesday 12th December 2017, 16:00 Brewing Up a Little Storm Event number: 849 291 546 Audio dial-in (phone): 01 526 0058 AMS InSight Monthly Webinar: Tuesday 12th December MicroB: Brewing

More information

Compliance of manufacturers of AST materials and devices with EUCAST guidelines

Compliance of manufacturers of AST materials and devices with EUCAST guidelines Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The

More information

Management of Hospital-acquired Pneumonia

Management of Hospital-acquired Pneumonia Management of Hospital-acquired Pneumonia Adel Alothman, MB, FRCPC, FACP Asst. Professor, COM, KSAU-HS Head, Infectious Diseases, Department of Medicine King Abdulaziz Medical City Riyadh Saudi Arabia

More information

SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* ...

SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* ... SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* The next-generation MicroScan WalkAway System combines proven technology and reliability with enhanced ease-of-use features to streamline

More information

Surveillance for Antimicrobial Resistance and Preparation of an Enhanced Antibiogram at the Local Level. janet hindler

Surveillance for Antimicrobial Resistance and Preparation of an Enhanced Antibiogram at the Local Level. janet hindler Surveillance for Antimicrobial Resistance and Preparation of an Enhanced Antibiogram at the Local Level janet hindler At the conclusion of this talk, you will be able to Describe CLSI M39-A3 recommendations

More information

Childrens Hospital Antibiogram for 2012 (Based on data from 2011)

Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical

More information

CUMULATIVE ANTIBIOGRAM

CUMULATIVE ANTIBIOGRAM BC Children s Hospital and BC Women s Hospital & Health Centre CUMULATIVE ANTIBIOGRAM 2017 Division of Medical Microbiology Department of Pathology and Laboratory Medicine Page 1 of 5 GRAM-POSITIVE BACTERIA

More information